Of mice and men: is there a future for metformin in the treatment of hepatic steatosis?
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver diseases, of which the first stage is steatosis. It is one of the most common liver diseases in developed countries and there is a clear association between type 2 diabetes (T2DM) and NAFLD. It is estimated that 70% of people...
Prif Awduron: | Green, C, Marjot, T, Tomlinson, J, Hodson, L |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
Wiley
2018
|
Eitemau Tebyg
-
Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes
gan: Marjot, T, et al.
Cyhoeddwyd: (2019) -
Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis
gan: Green, CJ, et al.
Cyhoeddwyd: (2022) -
Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
gan: Thomas Marjot, et al.
Cyhoeddwyd: (2020-06-01) -
Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?
gan: Tariq, Z, et al.
Cyhoeddwyd: (2014) -
Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?
gan: Tariq, Z, et al.
Cyhoeddwyd: (2014)